BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BIOTRONIK Study Assesses Innovative Intracardiac Impedance Sensing Technology for CRT Optimization


11/28/2012 1:38:15 PM

BERLIN, Germany, November 28, 2012—BIOTRONIK, a leading manufacturer of innovative medical technology, today announced that the first patient has been enrolled in the company’s BIO.Detect HF II study. The study’s goal is to investigate the clinical relevance of the innovative intracardiac impedance (ICI) sensing technology and its ability to assess hemodynamic parameters. The ICI technology is incorporated in the company’s new cardiac resynchronization therapy defibrillators (CRT-D) which includes the innovative Lumax 740 HF-T. The ICI sensor evaluates changes in impedance during the cycle of the heart and is expected to be a useful surrogate for several left ventricular (LV) hemodynamic parameters.

The new technology is set to improve cardiac resynchronization therapy for heart failure patients. As the ICI technology is integrated into the device and will work with traditional leads, patients do not need to undergo any further complex or time consuming invasive procedures. Once clinically proven, this ICI sensor will form the basis for several unique algorithms for highly specific detection of worsening heart failure, automatic AV- and VV-delay optimization and intraoperative selection of optimal left ventricular lead placement.

“The BIO.Detect HF II study will evaluate whether hemodynamic changes can be used to inform physicians about changes in cardiac output—and whether these measurements can be put to work to optimize resynchronization therapy,” explained Professor Dr. Peter Søgaard of Aalborg University in Denmark, coordinating clinical investigator for the study. “These much anticipated study results will form a basis for the development of an algorithm for therapy optimization for cardiac resynchronization therapy defibrillator patients.”

The multicenter, international, nonrandomized interventional study spans 15 European investigational sites and is open to 60 patients. Each patient is implanted with a BIOTRONIK Lumax 740 HF-T device and is then tracked daily with BIOTRONIK Home Monitoring®. BIOTRONIK’s remote monitoring system is unique because it allows continuous, automatic, wireless monitoring of patient status and device status with daily updates that are independent of any patient interaction. The ICI data will be compared with data obtained by validated echocardiographic reference methods. “Currently there is no reliable test that gives physicians sufficient time to intervene before a patient’s status becomes critical and the situation may result in acute hospitalization,” commented Dr. Klaus-Jürgen Gutleben, Heart and Diabetes Center, Bad Oeynhausen, Germany. “A continuous measurement of left ventricular volume would provide important information about disease progression and could be used to monitor heart failure and the optimization of CRT therapy.” “Our ICI feature is just one of the innovations BIOTRONIK has recently developed to broaden the range of options physicians have for diagnosis and therapy—and offer patients the best care possible,” explains Christoph Böhmer, President International, BIOTRONIK. “BIOTRONIK’s new Lumax 740 ICDs and CRT-Ds also feature ProMRI® technology, which along with our Linoxsmart ICD leads represent the world’s first tachycardia system approved for magnetic resonance scanning. Add to that a device longevity of up to 11 years, our Lumax 740 implants truly make a difference and enhance patients’ quality of life.”

Contact:

Manuela Schildwächter

Communications & PR Manager

BIOTRONIK SE & Co. KG

Woermannkehre 1

12359 Berlin

Tel. 49 (0) 30 68905 1466

Email: manuela.schidwaechter@biotronik.com

About BIOTRONIK SE & Co. KG

As one of the world’s leading manufacturers of cardiovascular medical devices, with several million devices implanted, BIOTRONIK is represented in over 100 countries by its global workforce of more than 5,600 employees. Known for having its finger on the pulse of the medical community, BIOTRONIK assesses the challenges physicians face and provides the best solutions for all phases of patient care, ranging from diagnosis to treatment to patient management. Quality, innovation and reliability define BIOTRONIK and its growing success—and deliver confidence and peace of mind to physicians and their patients worldwide.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES